2024-01-25 15:30:27 ET
Summary
- Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy.
- The company's stock is up over 160% in the past year and is trading at its highest value since late 2021.
- Vera's CEO believes that atacicept has the potential to be a disease-modifying treatment for IgA nephropathy, and the ongoing Phase 3 trial is progressing well.
- The competition in igAN has been intensifying, however, and with no approval expected until 2025, Vera's stock price looks a little vulnerable in the short term. Short interest recently climbed >20%.
Investment Overview
Vera Therapeutics, Inc. ( VERA ) shareholders will be celebrating today, as the Brisbane, California-based company shared positive 72-week data from the open label extension ("OLE") period of its Phase 2b ORIGIN clinical trial of its lead candidate atacicept in participants with IgA nephropathy (IgAN)....
Read the full article on Seeking Alpha
For further details see:
Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect